Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

NCT04450654 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT04450654
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04450654 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Withdrawn
Start date
May 31, 2022
Completion date
July 25, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune-mediated necrotizing myopathy